Supriya Lifescience Ltd., a cGMP-compliant company with a solid track record in API manufacturing and an emphasis on products from a range of therapeutic segments, including anti-histamine, anti-allergic, vitamin, anaesthetic, and anti-asthmatic, has released the unaudited financial statements for the Q3FY25 results. The corporation has expanded its operations to over 86 countries worldwide.
Key Consolidated Financial Highlights:
| Particulars | Q3 FY25 | Q3 FY24 |
| Revenues (in Rs Cr) | 185.65 | 140.07 |
| Gross Profit (in Rs Cr) | 123.87 | 85.45 |
| EBITDA (in Rs Cr) | 65.95 | 41.49 |
| EBITDA Margin | 35.50% | 29.60% |
| PAT (in Rs Cr) | 46.78 | 29.78 |
| PAT Margin | 25.2% | 21.30% |
| Quarterly EPS (in Rs) | 5.82 | 3.70 |
Key Highlights for Q3 FY25:
Supriya Lifescience Ltd.’s revenue increased by 33% year over year to Rs. 185.65 crore in the third quarter of FY25 from Rs. 140.07 crore in the same quarter the previous year.
In comparison to Q3 FY24’s gross profit of Rs. 85.45 crore, the gross profit for Q3 FY25 increased by 45% to Rs. 123.87 crore.
Compared to Q3 FY24, when EBITDA was Rs. 41.49 crore with an EBITDA margin of 29.60%, Q3 FY25’s EBITDA was Rs. 65.95 crore with an EBITDA margin of 35.50%. This represents a YoY improvement of 591 bps.
In Q3 FY25, the Profit After Tax (PAT) climbed 57% to Rs 46.78 crore from Rs 29.78 crore in Q3 FY24.
In Q3 FY25, the PAT Margin was 25.2%, while in Q3 FY24, it was 21.30%.
Speaking on the findings, Dr Satish Wagh, Chairman and Full-Time Director of Supriya Lifescience Ltd., stated: “Our Q3FY25 results highlight Supriya Lifescience’s dedication to providing value through operational excellence and strategic growth efforts. Our robust market presence and effective execution across therapeutic areas are demonstrated by the 33% year-over-year revenue growth and the astounding 45% increase in gross profit. Our ability to sustain profitability while investing in sustainable development is demonstrated by the consistent improvement in our EBITDA and PAT margins, which reached 35% and 25%, respectively.
